Industry Growth Insights published a new data on “Targeted Drug EGFR RTK Inhibitors for NSCLC Market”. The research report is titled “Targeted Drug EGFR RTK Inhibitors for NSCLC Market research by Types (Icotinib, Gefitinib, Erlotinib, Afatinib, Osimertinib, Brigatinib, Other), By Applications (Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC), By Players/Companies Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Beacon Pharmaceuticals, Boehringer Ingelheim, Pfizer, ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Drug International Limted, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited, Cipla Pharma, Dr Reddy's Laboratories, Zydus Cadila, Hetero Drugs, Intas Pharmaceuticals, Alkem Laboratories, RPG Life Sciences, Fresenius Kabi India”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report
By Type
Icotinib, Gefitinib, Erlotinib, Afatinib, Osimertinib, Brigatinib, Other
By Application
Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC
By Companies
Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Beacon Pharmaceuticals, Boehringer Ingelheim, Pfizer, ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Drug International Limted, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited, Cipla Pharma, Dr Reddy's Laboratories, Zydus Cadila, Hetero Drugs, Intas Pharmaceuticals, Alkem Laboratories, RPG Life Sciences, Fresenius Kabi India
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Report Segments:
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market is segmented on the basis of:
Types
Icotinib, Gefitinib, Erlotinib, Afatinib, Osimertinib, Brigatinib, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Beta Pharma
- AstraZeneca
- Natco Pharma
- Qilu Pharmaceutical
- Genentech (Roche Group)
- Mylan
- Teva
- OSI Pharmaceuticals
- Glenmark Pharmaceuticals
- Beacon Pharmaceuticals
- Boehringer Ingelheim
- Pfizer
- ARIAD Pharmaceuticals (Takeda)
- Genvio Pharma Limited
- Drug International Limted
- Everest Pharmaceuticals
- Incepta Pharmaceuticals Limited
- Cipla Pharma
- Dr Reddy's Laboratories
- Zydus Cadila
- Hetero Drugs
- Intas Pharmaceuticals
- Alkem Laboratories
- RPG Life Sciences
- Fresenius Kabi India
Highlights of The Targeted Drug EGFR RTK Inhibitors for NSCLC Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Icotinib
- Gefitinib
- Erlotinib
- Afatinib
- Osimertinib
- Brigatinib
- Other
- By Application:
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Targeted Drug EGFR RTK Inhibitors for NSCLC Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Targeted drug EGFR RTK inhibitors are medications that block the growth of cancer cells by blocking the activity of EGFR. These drugs are often used to treat advanced NSCLC.
Some of the major players in the targeted drug egfr rtk inhibitors for nsclc market are Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals, Glenmark Pharmaceuticals, Beacon Pharmaceuticals, Boehringer Ingelheim, Pfizer, ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Drug International Limted, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited, Cipla Pharma, Dr Reddy's Laboratories, Zydus Cadila, Hetero Drugs, Intas Pharmaceuticals, Alkem Laboratories, RPG Life Sciences, Fresenius Kabi India.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Targeted Drug EGFR RTK Inhibitors for NSCLC Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size & Forecast, 2018-2028
4.5.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Y-o-Y Growth
4.5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Absolute $ Opportunity
Chapter 5 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
5.2.1 Icotinib
5.2.2 Gefitinib
5.2.3 Erlotinib
5.2.4 Afatinib
5.2.5 Osimertinib
5.2.6 Brigatinib
5.2.7 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
6.2.1 Squamous Cell Carcinoma of NSCLC
6.2.2 Adenocarcinoma of NSCLC
6.2.3 Large Cell Carcinoma of NSCLC
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Analysis and Forecast
9.1 Introduction
9.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
9.6.1 Icotinib
9.6.2 Gefitinib
9.6.3 Erlotinib
9.6.4 Afatinib
9.6.5 Osimertinib
9.6.6 Brigatinib
9.6.7 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
9.10.1 Squamous Cell Carcinoma of NSCLC
9.10.2 Adenocarcinoma of NSCLC
9.10.3 Large Cell Carcinoma of NSCLC
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Analysis and Forecast
10.1 Introduction
10.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
10.6.1 Icotinib
10.6.2 Gefitinib
10.6.3 Erlotinib
10.6.4 Afatinib
10.6.5 Osimertinib
10.6.6 Brigatinib
10.6.7 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
10.10.1 Squamous Cell Carcinoma of NSCLC
10.10.2 Adenocarcinoma of NSCLC
10.10.3 Large Cell Carcinoma of NSCLC
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
11.6.1 Icotinib
11.6.2 Gefitinib
11.6.3 Erlotinib
11.6.4 Afatinib
11.6.5 Osimertinib
11.6.6 Brigatinib
11.6.7 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
11.10.1 Squamous Cell Carcinoma of NSCLC
11.10.2 Adenocarcinoma of NSCLC
11.10.3 Large Cell Carcinoma of NSCLC
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Analysis and Forecast
12.1 Introduction
12.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
12.6.1 Icotinib
12.6.2 Gefitinib
12.6.3 Erlotinib
12.6.4 Afatinib
12.6.5 Osimertinib
12.6.6 Brigatinib
12.6.7 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
12.10.1 Squamous Cell Carcinoma of NSCLC
12.10.2 Adenocarcinoma of NSCLC
12.10.3 Large Cell Carcinoma of NSCLC
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Targeted Drug EGFR RTK Inhibitors for NSCLC Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type
13.6.1 Icotinib
13.6.2 Gefitinib
13.6.3 Erlotinib
13.6.4 Afatinib
13.6.5 Osimertinib
13.6.6 Brigatinib
13.6.7 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Applications
13.10.1 Squamous Cell Carcinoma of NSCLC
13.10.2 Adenocarcinoma of NSCLC
13.10.3 Large Cell Carcinoma of NSCLC
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Competitive Dashboard
14.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Beta Pharma
14.3.2 AstraZeneca
14.3.3 Natco Pharma
14.3.4 Qilu Pharmaceutical
14.3.5 Genentech (Roche Group)
14.3.6 Mylan
14.3.7 Teva
14.3.8 OSI Pharmaceuticals
14.3.9 Glenmark Pharmaceuticals
14.3.10 Beacon Pharmaceuticals
14.3.11 Boehringer Ingelheim
14.3.12 Pfizer
14.3.13 ARIAD Pharmaceuticals (Takeda)
14.3.14 Genvio Pharma Limited
14.3.15 Drug International Limted
14.3.16 Everest Pharmaceuticals
14.3.17 Incepta Pharmaceuticals Limited
14.3.18 Cipla Pharma
14.3.19 Dr Reddy's Laboratories
14.3.20 Zydus Cadila
14.3.21 Hetero Drugs
14.3.22 Intas Pharmaceuticals
14.3.23 Alkem Laboratories
14.3.24 RPG Life Sciences
14.3.25 Fresenius Kabi India
